KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.

Carlos Mauricio Oliveira de Almeida, Manuelina Mariana Capellari Brito, Nayanne Beckmann Bosaipo, Angela Vieira Pimentel, Manoel Alves Sobreira-Neto, Vitor Tumas, Antonio Waldo Zuardi, Jose Alexandre de Souza Crippa, Jaime Eduardo Cecílio Hallak, Alan Luiz Eckeli

Cannabis Cannabinoid Res 8(2) 374-378

PMID35749710
PMCID-
DOI10.1089/can.2021.0158
发表日期2022-06-24
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Background: Cannabidiol (CBD) is one of the main nonpsychoactive components of Cannabis sativa and may represent an alternative treatment for Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) in patients with Parkinson's disease (PD) and REM (Rapid Eye Movement) sleep behavior disorder (RBD). Objective: Our purpose was a post hoc exploratory analysis to evaluate the CBD's efficacy to improve the severity of RLS/WED symptoms in patients with PD and RBD. Methods: A post hoc exploratory analysis of a phase II/III, a parallel, double-blind, placebo-controlled clinical trial was conducted in 18 patients with RLS/WED and PD plus RBD associated. Six patients were randomized to the CBD group in doses of 75-300 mg, and twelve received placebo capsules. They were followed up for 14 weeks. The primary outcome was the severity of RLS/WED by Restless Legs Syndrome Rating Scale of the International Restless Legs Syndrome Study Group (IRLSSG). Results: CBD showed no difference in relationship to placebo for primary and secondary outcomes. Conclusion: CBD showed no reduction in the severity of RLS/WED manifestation in patients with PD and RBD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。